Stock listing
PAB Stock Price, News, Filings & Events — Patrys Limited
Selected listing: PAB · ASX · AUD · AU
This page tracks Patrys Limited's PAB:ASX listing on ASX in AUD for AU, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PAB:ASX. PAB:ASX is the stock-level entry point for investors researching Patrys Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Patrys Limited (Ticker: PAB) is a public company based in Australia with a market capitalization of approximately AUD 17.94 million. The company focuses on developing innovative therapies for cancer treatment. Patrys is committed to advancing its research and development efforts to address unmet medical needs in oncology.

- Ticker
- PAB:ASX
- Asset type
- Stock
- Market cap
- $15.4M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- ASX
- Currency
- AUD
Patrys Limited PAB:ASX stock context
This page tracks Patrys Limited's PAB:ASX listing on ASX in AUD for AU, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PAB:ASX. PAB:ASX is the stock-level entry point for investors researching Patrys Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Patrys Limited (Ticker: PAB) is a public company based in Australia with a market capitalization of approximately AUD 17.94 million. The company focuses on developing innovative therapies for cancer treatment. Patrys is committed to advancing its research and development efforts to address unmet medical needs in oncology.
Latest news from Patrys Limited
Ethics Approval Secured for Phase 1A Clinical Trial
August 27, 2026
Investor Presentation - TechKnow Invest Roadshow
July 26, 2026
Appendix 4C - Quarterly - 30 June 2026
July 21, 2026
Patrys Secures 50% Revenue Share in IP Commercialisation
July 12, 2026
Patrys advances RLS-2202 toward Phase 1 Clinical Trial
May 19, 2026
Research Patrys Limited
Patrys Limited investor report
Review AI stock analysis and investor report context for PAB:ASX.
Patrys Limited company profile
View the public company page for Patrys Limited on 6ix.
Patrys Limited news
Read company news and market updates connected to Patrys Limited.
Patrys Limited investor events
Find investor webinars, events, and replay context for Patrys Limited.